Suppr超能文献

延迟期增强成像在恶性胸膜间皮瘤中的价值。

The value of delayed phase enhanced imaging in malignant pleural mesothelioma.

作者信息

Patel Akash M, Berger Ian, Wileyto E Paul, Khalid Urooj, Torigian Drew A, Nachiappan Arun C, Barbosa Eduardo M, Gefter Warren B, Galperin-Aizenberg Maya, Gupta Narainder K, Simone Charles B, Haas Andrew R, Alley Evan W, Singhal Sunil, Cengel Keith A, Katz Sharyn I

机构信息

Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.

出版信息

J Thorac Dis. 2017 Aug;9(8):2344-2349. doi: 10.21037/jtd.2017.07.86.

Abstract

BACKGROUND

Cross-sectional imaging of malignant pleural mesothelioma (MPM) can underestimate the presence of local tumor invasion. Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed. Here we estimate the optimal timing of MPM enhancement on magnetic resonance imaging (MRI).

METHODS

All MPM patients with intravenous (IV) contrast enhanced staging MRI between 2000-2016 at our institution were retrospectively selected for image analysis. Patients with incomplete imaging protocol and maximum pleural tumor thickness <1 cm were excluded. Quantitative measurements of tumor signal intensity were obtained on pre-contrast and post-contrast phases where MRI acquisition parameters were fixed. Using best-fit model curves, predicted maximum time points of enhancement were determined using a simulation of predicted values. Additionally, a qualitative assessment of tumor conspicuity was performed at all IV contrast time delays imaged. A statistical analysis assessed for correlation between qualitative lesion conspicuity and quantitative tumor enhancement.

RESULTS

Of the 42 MPM patients who had undergone staging MRI during the study period, 12 patients met the study criteria. Peak tumor enhancement was between 150 and 300 sec following IV contrast administration. Within this time window, 80% of patients are projected to have reached >80%, >85%, and >90% peak tumor enhancement. There was a statistically significant correlation between increasing tumor enhancement and subjective lesion conspicuity.

CONCLUSIONS

Optimal MPM enhancement on MRI likely occurs at a time delay between 2.5-5 min following IV contrast administration. Further study of delayed phase enhancement of MPM with dynamic contrast enhanced MRI is warranted.

摘要

背景

恶性胸膜间皮瘤(MPM)的横断面成像可能会低估局部肿瘤侵犯的存在。由于准确分期对治疗的最佳选择至关重要,因此需要优化胸膜成像的技术。在此,我们评估了磁共振成像(MRI)上MPM增强的最佳时间。

方法

回顾性选择2000年至2016年期间在我们机构接受静脉(IV)对比剂增强分期MRI检查的所有MPM患者进行图像分析。排除成像方案不完整且最大胸膜肿瘤厚度<1 cm的患者。在MRI采集参数固定的情况下,在对比剂前和对比剂后阶段获得肿瘤信号强度的定量测量值。使用最佳拟合模型曲线,通过预测值模拟确定预测的最大增强时间点。此外,在所有成像的IV对比剂时间延迟时对肿瘤的清晰度进行定性评估。进行统计分析以评估定性病变清晰度与定量肿瘤增强之间的相关性。

结果

在研究期间接受分期MRI检查的42例MPM患者中,12例符合研究标准。静脉注射对比剂后,肿瘤增强峰值出现在150至300秒之间。在此时间窗口内,预计80%的患者肿瘤增强峰值将达到>80%、>85%和>90%。肿瘤增强增加与主观病变清晰度之间存在统计学显著相关性。

结论

MRI上MPM的最佳增强可能发生在静脉注射对比剂后2.5至5分钟之间的时间延迟。有必要进一步研究动态对比增强MRI对MPM延迟期增强的作用。

相似文献

1
The value of delayed phase enhanced imaging in malignant pleural mesothelioma.
J Thorac Dis. 2017 Aug;9(8):2344-2349. doi: 10.21037/jtd.2017.07.86.
2
Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
Clin Lung Cancer. 2021 May;22(3):210-217.e1. doi: 10.1016/j.cllc.2020.06.002. Epub 2020 Jun 14.
3
4
5
Morphologic and functional imaging of malignant pleural mesothelioma.
Eur J Radiol. 2007 Dec;64(3):356-66. doi: 10.1016/j.ejrad.2007.08.010. Epub 2007 Oct 22.
8
What is the best way to diagnose and stage malignant pleural mesothelioma?
Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):254-9. doi: 10.1510/icvts.2010.255893. Epub 2010 Nov 1.
10
Interobserver Variability of Quantitative and Qualitative Assessment Using MRI in Malignant Pleural Mesothelioma.
Radiol Cardiothorac Imaging. 2020 Apr 30;2(2):e190066. doi: 10.1148/ryct.2020190066. eCollection 2020 Apr.

引用本文的文献

2
3
5
Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
Lung Cancer. 2019 Apr;130:108-114. doi: 10.1016/j.lungcan.2018.11.033. Epub 2018 Nov 28.
6
Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy.
Lung Cancer. 2018 Apr;118:48-56. doi: 10.1016/j.lungcan.2018.01.014. Epub 2018 Feb 3.

本文引用的文献

2
Diffusion magnetic resonance imaging of chest tumors.
Cancer Imaging. 2012 Oct 26;12(3):452-63. doi: 10.1102/1470-7330.2012.0041.
3
Initial analysis of the international association for the study of lung cancer mesothelioma database.
J Thorac Oncol. 2012 Nov;7(11):1631-9. doi: 10.1097/JTO.0b013e31826915f1.
8
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
AJR Am J Roentgenol. 1999 Apr;172(4):1039-47. doi: 10.2214/ajr.172.4.10587144.
9
Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability.
AJR Am J Roentgenol. 1992 Nov;159(5):961-6. doi: 10.2214/ajr.159.5.1414807.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验